Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis
NCT ID: NCT01499459
Last Updated: 2012-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
25 participants
INTERVENTIONAL
2008-06-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis
NCT02705742
Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
NCT01220492
A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis
NCT01877759
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
NCT01483248
Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis
NCT03209986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
autologous mesenchymal stem cell transplantation
autologous mesenchymal stem cell transplantation
Every patient is given 1x106 MSCs per kg infused via peripheral vein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous mesenchymal stem cell transplantation
Every patient is given 1x106 MSCs per kg infused via peripheral vein.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* absence of hepatocellular carcinoma or any malignancies
* no psychiatric disorder
* no serous cardiovascular and pulmonary comorbidities
* serum total bilirubin levels less than 5 mg/dL
* platelet counts more than 30.000 mm3
* more than one year follow up period after initiation of antiviral drugs
Exclusion Criteria
* initiation of antiviral medication in last one year
* systemic diseases
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Murat Kantarcioglu
Gulhane Military Medical Academy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
murat kantarcioglu, MD
Role: PRINCIPAL_INVESTIGATOR
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gulhane Military Medical Academy Department of Gastroenterology
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1111111
Identifier Type: OTHER
Identifier Source: secondary_id
11111111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.